SARS Mosaic S(M)
Description
Product Specs
Product Science Overview
The SARS-Associated Coronavirus Spike Mosaic S (M) Recombinant is a synthetic construct designed to study and potentially combat the severe acute respiratory syndrome coronavirus (SARS-CoV) and its variants, including SARS-CoV-2, the virus responsible for the COVID-19 pandemic. This recombinant protein is engineered to include various epitopes from the spike (S) protein, which is crucial for the virus’s ability to infect host cells.
The spike (S) protein of coronaviruses is a large glycoprotein that plays a key role in the virus’s entry into host cells. It is composed of two subunits:
- S1 Subunit: Contains the receptor-binding domain (RBD) that directly interacts with the host cell receptor, angiotensin-converting enzyme 2 (ACE2).
- S2 Subunit: Facilitates the fusion of the viral and host cell membranes, allowing the viral genome to enter the host cell.
The mosaic S (M) recombinant is designed to include conserved regions from both subunits, enhancing its potential to elicit a broad immune response.
The development of the SARS-Associated Coronavirus Spike Mosaic S (M) Recombinant involves several key steps:
- Epitope Selection: Using immunoinformatics tools, researchers identify highly immunogenic epitopes from the spike protein that can interact with B and T lymphocytes .
- Protein Engineering: These epitopes are combined with suitable adjuvants and linkers to create a stable and antigenic recombinant protein .
- Expression and Purification: The recombinant protein is expressed in a suitable host system, such as E. coli or mammalian cells, and purified for further study and potential vaccine development .
The primary application of the SARS-Associated Coronavirus Spike Mosaic S (M) Recombinant is in vaccine development. By including multiple conserved epitopes, this recombinant protein aims to provide broad protection against various coronavirus strains. Additionally, it can be used in:
- Serological Assays: To detect antibodies against SARS-CoV and SARS-CoV-2 in patient samples.
- Therapeutic Research: As a target for developing monoclonal antibodies and other therapeutic agents.
